RxDoctor Payments Data

Aruna Subramanian, MD

Infectious Disease · Stanford, CANPI 1356371082

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,500 of the $4,760 with a category attached, or 73.5%. Pfizer accounts for 73.5% of it on its own, with 1 other manufacturer making up the rest.

$4,760in general payments, 2019–2025

Across 2 payments — averaging $2380.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4K
  • Gilead$1K
$1,488,768in research payments, 2019–2025

Across 77 payments — averaging $19,335 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$808K
  • Regeneron$424K
  • Modernatx, Inc.$250K
  • Novartis$7K

What the payments were for

  • Consulting fees$1,26026%
  • Speaking & faculty fees$3,50074%

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$3,500
Gilead1$1,260

How this compares

$4,760 in reported general payments places this provider in the 80th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$51,748
Medicare patients
134
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErtapenemErtapenem Sodium13$2,913
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$503
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$410

Paid to pharmacies, not to this prescriber.

Other infectious disease in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →